

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Bertrand Arnulf,¹ Halyna Pylypenko,² Sebastian Grosicki,³ Ievgenii Karamanesht,⁴ Xavier Leleu,⁵ Helgi van de Velde,⁶ Huaibao Feng,⁷ Andrew Cakana,⁸ William Deraedt,⁶ and Philippe Moreau⁹

¹Immuno-Hématologie Department, Hôpital Saint-Louis/Centre d'Investigations Cliniques, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, France; ²Cherkassy Regional Oncology Dispensary, Cherkassy, Ukraine; ³Oddzial Hematologiczny ZSM, Chorzow, Poland; ⁴Kiev BMT Center, Ukraine; ⁵Hopital Huriez, CHRU, Lille, France; ⁶Janssen Research & Development, Beerse, Belgium; ⁷Janssen Research & Development, Raritan, NJ, USA; ⁸Janssen Research & Development, High Wycombe, Buckinghamshire, UK; and ⁹University Hospital, Nantes, France

Citation: Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, and Moreau P. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. *Haematologica* 2012; 97(12):1925-1928. doi:10.3324/haematol.2012.067793

Online Supplementary Figure S1. Updated CONSORT diagram of patient disposition and flow through study protocol.

